

Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series
Reviewing Key Data and Presentations from the 62nd ASH Annual Meeting —
Chronic Lymphocytic Leukemia (Part 4)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Results of the Phase III CLL14 study demonstrated improved outcomes with which regimen compared to chlorambucil/obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting medical conditions?**
 - a. Venetoclax/rituximab
 - b. Venetoclax/obinutuzumab**
 - c. Bendamustine/obinutuzumab
- 2. In the ongoing Phase I/II BRUIN trial, which Bruton tyrosine kinase (BTK) inhibitor has demonstrated promising activity as a single agent for patients with previously treated CLL?**
 - a. Acalabrutinib
 - b. Zanubrutinib
 - c. LOXO-305 (pirtobrutinib)**
 - d. Duvelisib
- 3. Which of the following drug types best characterizes the mechanism of action of the novel agent umbralisib?**
 - a. Bcl-2 inhibitor
 - b. BTK inhibitor
 - c. CAR (chimeric antigen receptor) T-cell therapy
 - d. PI3K inhibitor**
- 4. The Phase III MURANO trial evaluating the efficacy of fixed-duration treatment with venetoclax/rituximab compared to bendamustine/rituximab for patients with relapsed/refractory CLL reported which of the following outcomes?**
 - a. Improvement in progression-free survival in the venetoclax study arm**
 - b. Similar progression-free survival in both arms